Meet our clinical advisory
Our Clarifi clinical advisory board is comprised of some of the top autism and epigenetic scientists and clinicians.
Diana L. Robins, PhD
Professor and the Interim Director of the AJ Drexel Autism Institute at Drexel University
Diana L. Robins, Ph.D. is a Professor and the Interim Director of the AJ Drexel Autism Institute at Drexel University. She also leads the Research Program in Early Detection and Intervention for ASD. She holds secondary appointments in Community Health and Prevention in the Dornsife School of Public Health and Psychology in the College of Arts and Sciences at Drexel University. Much of her work has centered around developing, validating, and refining a widely- used screening tool for ASD, the Modified Checklist for Autism in Toddlers, or M-CHAT. The original M-CHAT paper has been cited more than 1600 times, and the validation of the recent revision, M-CHAT-R with Follow-Up (M-CHAT-R/F), demonstrated that the 2-stage screening questionnaire detects many cases of autism, and children in the study were diagnosed about two years younger than the national median, which improves access to ASD-specific early intervention. Her current studies examine the optimal ages for primary care screening to detect autism risk, and a new Autism Center of Excellence (ACE) network to relate early detection in primary care to early intervention and positive outcomes by age 5. Dr. Robins’ research has been funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Autism Speaks, and the National Institute of Mental Health. Her work has been published in leading pediatric and autism journals. She currently serves on the editorial boards of the Journal of Autism and Developmental Disorders and Autism: The International Journal of Science and Practice, and is the treasurer of the International Society for Autism Research. Dr. Robins received her doctorate in Clinical Psychology, with an emphasis in Clinical Neuropsychology from the University of Connecticut. Following her APA-approved internship at the University of Florida Health Sciences Center, Dr. Robins completed a 2-year postdoctoral fellowship at the Yale University School of Medicine Child Study Center. She then spent 10 years on the faculty at Georgia State University, with a joint appointment in the Department of Psychology and the Neuroscience Institute, before moving to Drexel University in 2014. She is delighted that her program at the AJ Drexel Autism Institute draws students from public health, psychology, and medicine to work together on public health approaches to improving early detection and intervention for ASD.
Daniel L. Coury, MD
Professor of Pediatrics and Psychiatry in the College of Medicine at The Ohio State University
Daniel L. Coury, MD is Professor of Pediatrics and Psychiatry in the College of Medicine at The Ohio State University and in the Section of Developmental and Behavioral Pediatrics for Nationwide Children’s Hospital in Columbus, Ohio. He has served on the Sub-board on Developmental-Behavioral Pediatrics of the American Board of Pediatrics, the American Board of Psychiatry and Neurology Steering Committee for Child and Adolescent Psychiatry, and on the Executive Committee of the Council of Pediatric Subspecialties. Dr. Coury is a Past President of the Academic Pediatric Association and Past President of the Society for Developmental and Behavioral Pediatrics (SDBP). In 2000 he was honored for his special contributions to developmental-behavioral pediatrics by SDBP. He has a long history of working with the federal Maternal and Child Health Bureau (MCHB), having been a MCHB Developmental-Behavioral Pediatrics Program Director, a Leadership Education in Neurodevelopmental Disabilities (LEND) Director and Medical Director of a University Center for Excellence in Developmental Disabilities (UCEDD). He has published over 80 peer reviewed articles and participated in over 40 clinical trials of vaccines and treatments for ADHD, anxiety and autism. His current primary focus is in his role as Medical Director for the Autism Speaks Autism Treatment Network (ATN) and the HRSA MCHB funded Autism Intervention Research Network on Physical Health (AIR-P). His current research activities include work on early identification of autism, improving dental care for people with autism, promoting transition of people with autism to adult health care and other services, and improving medical care for people with autism through training of primary care providers.
Evdokia Anagnostou, MD
Child neurologist and senior clinician scientist at Holland Bloorview Kids Rehabilitation Hospital
Dr. Evdokia Anagnostou, MD, is a child neurologist and senior clinician scientist at Holland Bloorview Kids Rehabilitation Hospital; associate professor in the department of pediatrics at the University of Toronto; Assistant Director of Holland Bloorview’s Research Institute and co-lead of the Autism Research Centre (ARC). She holds a Canada Research Chair in translational therapeutics in Autism Spectrum Disorder (ASD) and the Dr. Stuart D. Sims Chair in Autism at Holland Bloorview. Dr. Anagnostou’s research focuses on translating genomic and systems biology findings into novel treatments for ASD.
David Beversdorf, MD
MD, Principal Investigator, Professor (Radiology, Neurology, and Psychology) University of Missouri Health, School of Medicine
Dr. Beversdorf graduated from Indiana University and completed Neurology residency at Dartmouth. After his fellowship in Behavioral Neurology at University of Florida, he joined the Ohio State University faculty. He has published on memory disorders, autism, cognitive neuroscience, fMRI, neurpsychopharmacology and drug addiction. He joined the University of Missouri (Radiology, Neurology, Psychology and the Thompson Center) to focus on autism, with particular interest in pharmacofMRI as a potential treatment marker, and gene/stress interactions in autism. Dr. Beversdorf’s work has been published in journals such as Neurology, Journal of Neurology Neuroscience and Psychiatry, Proceedings of the National Academy of Sciences of the United State of America and Lancet. He is also actively involved in the Brain Imaging Center at the University of Missouri. His research has been funded by National Institute of Neurological Diseases and Stroke, National Institute On Drug Abuse, Department of Defense, Autism Treatment Network, the Stallone Fund and the National Alliance for Autism Research. He has joined the University of Missouri in the departments of Radiology, Neurology, Psychology and the Thompson Center as the William and Nancy Thompson Endowed Chair in Radiology to focus on the field of autism, with particular interest in pharmaco-functional neuroimaging as a potential treatment marker, as well as other biomarkers for treatment, and gene/stress interactions in the development of autism.
Steven Hicks, MD PhD
Penn State Health Milton S. Hershey Medical Center
Dr. Hicks is an Assistant Professor of Academic General Pediatrics at Pennsylvania State College of Medicine in Hershey, PA. He is a physician scientist who studies the influence of genetics and the environment on pediatric diseases involving growth and neurodevelopment. More specifically, Dr. Hicks is interested in how peripheral epigenetic factors such as microRNA may be utilized to predict patient oriented outcomes in pediatric disorders of neurodevelopment (e.g. autism, concussion) and growth (e.g. annorexia nervosa, obesity). His research has been recently published in JAMA Pediatrics and the Journal of Neurotrauma.
Kristin Sohl, MD, FAAP
MD, FAAP Associate Professor, Clinical Child Health Vice Chair for Quality Improvement, Child Health Department Advocacy Director, Child Health Department Director, ECHO Autism
Kristin Sohl, MD, FAAP is an Associate Professor of Clinical Child Health at the University of Missouri, Thompson Center for Autism and Neurodevelopmental Disorders and Vice Chair of the Child Health Department. She is a pediatrician with extensive experience in medical diagnosis, evaluation and treatment of children with a concern of autism and other neurodevelopmental disorders. Dr. Sohl is regarded as an expert in quality and process improvement for comprehensive autism diagnostic and longitudinal services. She is the site principal investigator for the Autism Intervention Research for Physical Health/Autism Treatment Network (AIRP/ATN) and serves in national leadership roles with each of these programs. She is the founder of ECHO Autism, an innovative framework to increase community capacity to care for children with autism and other developmental/behavioral concerns. The ECHO Autism program is viewed as a national model in expanding autism diagnosis and treatment to underserved and rural populations-those currently faced with the longest wait times. The ECHO Autism team has established partnerships with other children’s hospitals and autism centers in more than 15 states and 5 countries. Her research focuses on systems change to improve healthcare and also focuses on understanding underlying medical conditions in individuals with autism. Dr. Sohl is a tireless advocate for children and enjoys engaging other physicians in being a voice for children’s health. She is the President Elect of the American Academy of Pediatrics, Missouri Chapter. She completed medical school and pediatric residency at the University of Missouri.
Frank Middleton, PhD
SUNY Upstate Medical University
Dr. Frank Middleton is an Associate Professor in the Department of Neuroscience & Physiology, Department of Psychiatry & Behavioral Sciences and the Department of Biochemistry & Molecular Biology at SUNY Upstate Medical University. He is the founder and director of the SUNY Molecular Analysis Core facility, which specializes in next-generation sequencing analysis, and has published more than 120 peer-reviewed articles and a dozen book chapters. He is a chief section editor for Behavioral Brain Functions and Frontiers in Genetics.
Randy Carpenter, MD
Executive Vice President - Clinical Development Quadrant Biosciences
Dr. Carpenter has over 30 years experience in primary care, academic medicine, basic science and clinical research, and pharmaceutical drug development. His experience in the pharmaceutical and biotechnology industries include Co-Founder, President and CEO of Seaside Therapeutics, President and CEO of Sention, VP of Clinical Research & Development and Regulatory Affairs at Adolor Corporation and member of Astra Pain Control’s Global Therapeutic Area Team. While in industry, Dr. Carpenter led translational medicine teams responsible for 8 successful IND submissions and dozens of GCP-compliant clinical trials. Prior to joining industry, he held academic faculty appointments at Virginia Mason Medical Center, the University of Washington and Wake Forest University where he specialized in anesthesiology, pain management and translational medicine.